Doing more to incorporate caregiver burden into value assessments and cost-effectiveness research of Duchene muscular dystrophy treatments was the focus of a recent International Society for ...

Participants in the FORWARD-53 trial had clinically significant improvements in time-to-rise, among other metrics.

the country's leading funder of Duchenne muscular dystrophy (DMD) research, is set to begin accepting innovative research proposals as of March 31, 2025. They are seeking projects focused on ...

Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida, discusses gene therapy considerations for pediatric patients and how newborn screening can influence outcomes for ...

Santhera Pharmaceuticals will launch its new drug for Duchenne muscular dystrophy in the UK within the next few weeks, after getting confirmation it will be covered by the NHS in all four nations.

Dyne Therapeutics Inc. is advancing novel therapeutics for people living with genetically driven neuromuscular diseases.

Italfarmaco’s oral HDAC inhibitor givinostat has been approved in the US as a treatment for Duchenne muscular dystrophy (DMD), becoming the first non-steroidal option for patients with all ...

Considering taking supplements to treat muscular dystrophy? Below is a list of common natural remedies used to treat or reduce the symptoms of muscular dystrophy. Follow the links to read common ...

The view that the electrocardiographic abnormalities in Duchenne dystrophy are a manifestation of the dystrophic process in the myocardium is discussed. The authors' material, however, failed to ...

Spinal muscular atrophy (SMA) is a disorder affecting the motor neurons—nerve cells that control voluntary muscle movement. These cells are located in the spinal cord. Because the muscles cannot ...